Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Charles River Laboratories | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Charles River Laboratories

No rebound yet for preclinical services

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Charles River Laboratories 2Q10

2Q Revenues: $292 million (-5%)

2Q Earnings: $15 million (-57%)

YTD Revenues: $589 million (-3%)

YTD Earnings: $31 million (-46%)

Comments: The Research Models and Services (RMS) unit was flat at $166 million for the quarter. Gains from in vitro products were offset by lower sales of large models. The Preclinical Services (PCS) business saw revenues drop 12% to $125 million in 2Q10, driven by lower prices and reduced demand. The PCS unit reported more short-term, less complex studies. For 1H10, RMS revenues were up 4% to $339 million, while PCS sales were down 12% to $250 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters